ReviewFrontiers in pharmacology2026
Induction of immunogenic cell death by active components of natural products reshaping the tumor microenvironment for enhanced antitumor immunity.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immunosuppressive tumor microenvironment (TME) is a principal factor limiting the success of current cancer immunotherapies. Immunogenic cell death (ICD), a process whereby dying tumor cells elicit an adaptive immune response through the emission of damage-associated molecular patterns (DAMPs), offers a promising strategy to counteract this limitation. Natural products (NPs) constitute a valuable reservoir of compounds capable of triggering ICD. Purpose: This review aims to provide a comprehensive overview of ICD inducers derived from NPs, detail their molecular mechanisms of action, and explore their capacity to remodel the immunosuppressive TME. Methods: We performed a comprehensive literature search in relevant electronic databases to identify studies describing NPs-based components that stimulate characteristic ICD markers, such as surface exposure of calreticulin (CRT), and extracellular release of ATP and high mobility group box 1 (HMGB1). Results: Active components of NPs were demonstrated to initiate ICD largely via the induction of endoplasmic reticulum (ER) stress and reactive oxygen species (ROS). The consequent emission of DAMPs facilitates dendritic cell-mediated phagocytosis of tumor antigens and the priming of cytotoxic T lymphocytes. Additionally, the inflammatory milieu generated by NPs-induced ICD reprograms the TME by promoting the repolarization of macrophages to an immunostimulatory M1 phenotype and inhibiting the suppressive functions of myeloid-derived suppressor cells (MDSCs). Conclusion: Inducing ICD with NPs is a viable therapeutic strategy to potentiate anti-tumor immunity. The convergence of NPs-based ICD inducers with nanotechnology-based delivery systems offers a robust platform for the development of innovative combination regimens aimed at improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.